Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 1:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 3,324 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Diseases Clear all
Withdrawn Phase 1 Interventional

Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer

NCT02868632
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
MEDI4736, Tremelimumab, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 19, 2026, 1:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer

NCT00889187
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Neoadjuvant Short-Course Photon Radiation, Capecitabine
Radiation · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 19, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control

NCT02679287
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
CLC
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2020 · Synced Oct 19, 2026, 1:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

NCT03649321
View directory record Official record
Conditions
Cancer of Pancreas
Interventions
Bemcentinib, Nab-paclitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2023 · Synced Oct 19, 2026, 1:46 PM EDT
Completed No phase listed Observational

HERO-2: Home-Reported Outcomes With CFTR Modulator Therapy

NCT04798014
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
12 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 19, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

NCT00005832
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
R115777
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
14
States / cities
Los Angeles, California • Martinez, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 19, 2026, 1:46 PM EDT
Withdrawn Phase 2 Interventional

CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)

NCT06110598
View directory record Official record
Conditions
Pancreas Cancer, Pancreas Adenocarcinoma
Interventions
Capecitabine
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 19, 2026, 1:46 PM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

NCT02586987
View directory record Official record
Conditions
Lung Cancer, Melanoma, Head and Neck Carcinoma, Gastroesophageal Cancer, Breast Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Biliary Tract Cancer
Interventions
Selumetinib, MEDI4736, Tremelimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
6
States / cities
Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 19, 2026, 1:46 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of Armed, Activated T-Cells in Patients With Advanced Pancreatic Cancer

NCT04137536
View directory record Official record
Conditions
Pancreatic Cancer, Advanced Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Neoplasms
Interventions
anti-EGFR-bispecific antibody armed activated T-cells
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
New York, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 19, 2026, 1:46 PM EDT
Completed Not applicable Interventional Results available

Comparison of MRI and Molecular Breast Imaging in Breast Diagnostic Evaluation

NCT00591864
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Oct 19, 2026, 1:46 PM EDT
Withdrawn Not applicable Interventional

Laparoscopic Versus Open Pancreatectomy

NCT00988793
View directory record Official record
Conditions
Pancreatectomy
Interventions
Laparoscopic distal pancreatectomy, Open distal pancreatectomy
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 19, 2026, 1:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea

NCT00572975
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency
Interventions
Pentadecanoic acid (PA) and Triheptadecanoin (THA)
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years and older
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2008 · Synced Oct 19, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

NCT02893930
View directory record Official record
Conditions
Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2, Refractory Pancreatic Neuroendocrine Carcinoma
Interventions
Sapanisertib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
405
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 260 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Oct 19, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

NCT02575300
View directory record Official record
Conditions
Carcinoid Tumors, Pancreatic NET
Interventions
Ibrutinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2020 · Synced Oct 19, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma

NCT02289898
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Demcizumab, Abraxane®, gemcitabine, Placebo
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
22
States / cities
Gilbert, Arizona • Burbank, California • Duarte, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Oct 19, 2026, 1:46 PM EDT
Completed Phase 1 Interventional Results available

Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma

NCT00735306
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Avastin, Tarceva, Radiation Therapy
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 19, 2026, 1:46 PM EDT
Completed Phase 3 Interventional Results available

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

NCT01180634
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Aeroquin, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
95
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 19, 2026, 1:46 PM EDT
Recruiting No phase listed Observational

iMmune SignAtures and Clinical outComes in AP

NCT05878236
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
CyTOF Analysis
Diagnostic Test
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 75 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 1:46 PM EDT
Terminated Phase 1 Interventional Results available

A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

NCT03948763
View directory record Official record
Conditions
Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
Interventions
V941, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 19, 2026, 1:46 PM EDT
Completed Phase 2 Interventional

PTC124 for Cystic Fibrosis

NCT00234663
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
PTC124
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
5
States / cities
Birmingham, Alabama • Palo Alto, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2009 · Synced Oct 19, 2026, 1:46 PM EDT
Recruiting No phase listed Observational

Determining Individualized Cancer Therapy in Pancreatic Cancer

NCT05914987
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Targeted Therapy
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 19, 2026, 1:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Vorinostat Plus Radiation Therapy in Pancreatic Cancer

NCT00831493
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Chemoradiation (Radiation Therapy), Vorinostat
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 19, 2026, 1:46 PM EDT
Completed Phase 2 Interventional Results available

Bupropion in Helping Adults Stop Smoking

NCT00534001
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
bupropion hydrochloride, placebo
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 19, 2026, 1:46 PM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

NCT06881992
View directory record Official record
Conditions
Tumor Hyperinsulinism (Tumor HI)
Interventions
Ersodetug
Drug
Lead sponsor
Rezolute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Chicago, Illinois • Bethesda, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 19, 2026, 1:46 PM EDT